Keya Medical Technology Co.

Seattle, Washington, USA, and Beijing, China (with offices in Shanghai and Shenzhen) [1, 2, 4, 5, 6, 7, 8, 16]  All China companies → — Founded 2016
Imaging AI Specialist Specialty-Focused AI
Cardiology Cardiothoracic Surgery Radiology
Cardiology AI Radiology & Imaging AI
Series D (last reported Series D funding in January 2021) [11] — Over $111.74 million (also cited as $30.2M in 1 round, $144M, and $325.81M) [3, 4, 5, 7, 11]

Products

DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.

See all 1 product →

About Keya Medical Technology Co.

Keya Medical Technology Co. is an international medical technology company specializing in deep learning-based AI solutions for non-invasive disease diagnosis and treatment. The company, founded in 2016, develops AI-enabled diagnostic devices that aim to enhance efficiency, accuracy, and precision in healthcare across various specialties, including cardiology, neurology, pulmonology, pathology, and surgery. [2, 4, 8, 14]

Keya Medical’s flagship product, DEEPVESSEL FFR, is a CT-derived fractional flow reserve (CT-FFR) analysis software. This non-invasive tool utilizes deep learning technology to perform physiological functional assessments of coronary arteries from coronary computed tomography angiography (CCTA) scans. [1, 2, 8, 14, 16] It has received regulatory clearances from major markets, including CE Mark approval (2018), Chinese NMPA clearance (2020), and US FDA clearance (2022). [2, 8, 12, 14, 16] The company also offers DeepVessel Plaque, an AI-powered coronary plaque analysis tool for CCTA, which received FDA 510(k) clearance in June 2026. [17, 18] This software provides quantitative measurements of plaque volume, stenosis severity, and CAD-RADS categorization. [17] Keya Medical collaborates with hospitals and key opinion leaders globally, with its products being used in numerous hospitals and cardiac care centers. [4, 6, 11, 12]

Focus Areas

medical imaging AI deep learning diagnostic assistance cardiovascular AI neurological AI oncology AI

Business Intelligence

Key InvestorsTencent, GL Ventures, Morningside Venture Capital, 5Y Capital, CICC Capital, China Merchants Venture, Shanghai Guosheng Capital
Partnershipsunknown
Acquisitionsunknown
Technologycloud-native AI platform, deep learning algorithms
FDA Clearancesunknown cleared products (estimated)

What Physicians Need to Know

Medical Imaging AI & Deep Learning
Keya Medical specializes in deep learning algorithms for medical imaging and bioinformatics. Their solutions are FDA-cleared and leverage AI to enhance diagnostic accuracy and efficiency.
Cardiovascular AI
A primary focus is on cardiovascular care, offering FDA-cleared deep learning solutions for comprehensive coronary CTA assessment. This includes quantitative plaque analysis (DEEPVESSEL Plaque) and CT-derived fractional flow reserve (DEEPVESSEL FFR) to support clinical decision-making from a single CCTA examination.
Diagnostic Assistance
Their flagship product, DEEPVESSEL FFR, provides a non-invasive physiological functional assessment of coronary arteries, aiming to reduce unnecessary invasive procedures like coronary angiography and stent implantation.
Neurological AI
Keya Medical has developed AI software for triaging time-sensitive intracranial hemorrhage from head CT scans.
Oncology AI
While their primary focus is cardiovascular, Keya Medical's broader commitment extends to developing AI-enabled diagnostic devices across various specialties, including oncology.
Key Differentiators
Key differentiators include FDA-cleared, deep learning-based solutions for non-invasive functional assessment (DEEPVESSEL FFR) and quantitative plaque analysis (DEEPVESSEL Plaque) from CCTA. Their technology offers high diagnostic accuracy, comprehensive anatomical and functional information, and a streamlined workflow.
Technology Stack
Keya Medical utilizes cutting-edge deep learning neural networks and algorithms for medical image processing, model reconstruction, and intelligent optimization. Their solutions are cloud-based, allowing for secure image transfer and efficient analysis.
Physician Tip

For physicians, Keya Medical's solutions offer precise, comprehensive, and efficient tools for diagnosing and managing cardiovascular disease. DEEPVESSEL FFR provides non-invasive functional assessment from CCTA, potentially reducing the need for invasive procedures. The interactive 3D models and detailed reports allow for quick identification of lesions and comprehensive observation of vascular structures, supporting confident clinical decision-making. The cloud-based platform and streamlined workflow eliminate the need for extensive software investments or staff training, making it convenient and cost-effective to integrate into daily practice.

Keya Medical's solutions are designed for seamless integration into existing clinical workflows. Studies can be securely uploaded to a cloud platform (e.g., PIA Cloud), automatically routed for analysis, and comprehensive reports, including interactive 3D models and FFR values, are promptly returned to the client's Picture Archiving and Communication System (PACS). They also collaborate with partners like Precision Image Analysis (PIA) and Corazon Imaging to offer cloud-based, on-demand post-processing services and integrate CT FFR into mobile radiology services.

Products by Keya Medical Technology Co.

1 product in the directory

DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.

Reviews & Opinions

No web reviews on file yet for Keya Medical Technology Co.. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Keya Medical Technology Co..

Loading videos...

Videos load interactively. If none appear, search YouTube for Keya Medical Technology Co. →

View all on YouTube

Press & Coverage

DeviceClaims
Keya Medical's DEEPVESSEL Plaque Clears FDA as Automated Coronary Image-Processing Software
Keya Medical Technology Co., Ltd. received FDA 510(k) clearance for its DEEPVESSEL Plaque software on June 4, 2026. This AI-powered tool is designed for automated coronary image processing and plaque analysis, operating on already-acquired images to quantify vessel wall characteristics.
2026-06
FDA
K260497 - 510(k) Premarket Notification - FDA
The FDA's 510(k) Premarket Notification for Keya Medical Technology Co., Ltd.'s DEEPVESSEL Plaque (K260497) was cleared on June 4, 2026. The device is classified as a Class II medical image management and processing system with product code QIH.
2026-06
FDA
List of Artificial Intelligence-Enabled Medical Devices - FDA
Keya Medical Technology Co., Ltd. is listed among Artificial Intelligence-Enabled Medical Devices by the FDA, with their DEEPVESSEL Plaque device (K260497) cleared on June 4, 2026.
2026-09
Journal of Geriatric Cardiology
CT-derived fractional flow reserve combined with atherosclerotic extent to determine long-term outcomes in diabetic patients with coronary artery disease - Journal of Geriatric Cardiology
A study published in the Journal of Geriatric Cardiology in December 2025 utilized Keya Medical Technology Co., Ltd.'s DEEPVESSEL FFR workstation for deep learning-based CT-FFR calculations in diabetic patients with coronary artery disease. The study aimed to examine the long-term prognostic value of CT-FFR combined with CCTA-defined atherosclerotic extent.
2025-12
Journal of the American Heart Association
Prognostic Significance of Computed Tomographyu2010Derived Fractional Flow Reserve for Longu2010Term Outcomes in Individuals With Coronary Artery Disease - PMC
A January 2025 article in the Journal of the American Heart Association describes a retrospective pooled analysis that used Keya Medical Technology Co., Ltd.'s deep-learning-based CT-FFR for assessing long-term outcomes in patients with coronary artery disease. The study found that CT-FFR u22640.80 exhibited robust predictive value for major adverse cardiovascular events.
2025-01
ResearchAndMarkets.com
AI in Medical Imaging: From Experimentation to Operation - Market Projections & Trends - ResearchAndMarkets.com
A September 2025 report on AI in Medical Imaging from ResearchAndMarkets.com lists Shenzhen Keya Medical Technology Co., Ltd. as a key vendor in the market. The report provides market projections and trends, highlighting the growth of AI in medical imaging.
2025-09
unknown
Impact of Diabetes on Management and Outcomes in Patients with Borderline FFR CT
A study published in December 2025 investigated the impact of diabetes on the management and outcomes of patients with borderline CT-derived fractional flow reserve (FFRCT), utilizing Keya Medical Technology Co., Ltd.'s DEEPVESSEL FFR workstation. The study found that diabetic patients had a significantly higher prevalence of invasive coronary angiography and revascularization.
2025-12
Caixin Global
Computer-Assisted Diagnostics Firm Shukun Files for Hong Kong Listing - Caixin Global
In September 2021, Caixin Global reported that Beijing Keya Medical Technology Co. Ltd. had submitted its plans to the HKEX for listing, alongside other computer-assisted medical diagnosis firms.
2021-09

Frequently Asked Questions

Keya Medical Technology Co. primarily offers AI-powered solutions for cardiovascular imaging and diagnostics. Their flagship product, DEEPVESSEL FFR, is an FDA-cleared, CE-marked, NMPA-approved, and HSA-certified software that uses deep learning to non-invasively assess coronary artery function from CT angiography (CCTA) scans. They also have DeepVessel Plaque, an FDA-cleared AI-powered tool for quantitative coronary plaque analysis from CCTA. While their primary focus is cardiovascular, Keya Medical is also developing AI-enabled diagnostic devices for neurology, pulmonology, pathology, and surgery, and previously received FDA clearance for intracranial hemorrhage triage software.
Keya Medical's flagship product, DEEPVESSEL FFR, has received significant international regulatory clearances, including FDA clearance in the US (2022), CE Mark in Europe (2018), NMPA approval in China (2020), and HSA certification in Singapore (2023). Their DeepVessel Plaque software also received FDA 510(k) clearance in 2026. These certifications demonstrate their adherence to stringent safety, effectiveness, and quality standards for commercial availability in these regions.
Keya Medical ensures accuracy and clinical validation through multi-center studies. For example, DEEPVESSEL FFR's diagnostic performance was validated in the ADAPT study, a multi-national, multi-center clinical trial involving 269 patients across 10 clinical sites in the US and EU. This study demonstrated good diagnostic performance in detecting ischemic conditions compared to invasive FFR measurements. Similarly, DeepVessel Plaque's FDA clearance was supported by a multicenter clinical validation study at three U.S. sites, showing strong agreement with expert consensus for plaque quantification and CAD-RADS categorization.
Keya Medical actively pursues strategic partnerships to expand its reach and integrate its AI solutions. They collaborate with companies like Precision Image Analysis (PIA) and Corazon Imaging to offer cloud-based, on-demand post-processing services for their AI FFR CT solution, eliminating the need for expensive software investments. They also partner with organizations like Kanbai Tech to further implement their CT-FFR technology in new markets, such as Spain, leveraging their distribution networks. These partnerships aim to streamline diagnostic workflows, improve patient care, and provide accessible cloud technology and mobile radiology services.
Keya Medical, founded in 2016, has demonstrated financial stability, securing over $111.74 million in funding, including a $46 million Series D round in 2021. This funding supports their AI product development and global business expansion. The company has a long-term vision of developing deep learning-based medical devices across various specialties, with a primary focus on cardiovascular care, and has established an AI diagnostic laboratory. They are committed to continuous innovation and have a pipeline of 11 products in development.

Related Companies

Intelligent Voice AI (IVAI) is an agentic AI platform that deploys AI voice agents specifically designed for healthcare, insurance, legal, and home services businesses. For physicians and medical practices, IVAI’s Evolve AI Agents act as an AI workforce, not just an answering service, handling a comprehensive range of administrative and operational tasks. These agents can […]

Dext, formerly known as Receipt Bank, is a company that specializes in bookkeeping automation, leveraging data, technology, and applied AI to enhance productivity and efficiency for businesses, accountants, and bookkeepers. [3, 16] Their platform is designed to streamline financial document management and automate bookkeeping tasks, aiming to simplify the accounting process and enable more informed […]

Cortex (https://www.cortex.app) is an AI-powered internal developer portal designed to enhance engineering excellence and streamline software development workflows. For physicians, this translates to a platform that can indirectly improve healthcare technology by enabling engineering teams to build more reliable, secure, and efficient software. The platform helps in cataloging, scoring, and assigning actions to improve service […]

Nino is an AI-powered financial planning and tax service that aims to provide comprehensive financial guidance. For physicians, Nino’s AI software can help manage income, student loans, and plan career transitions, such as moving from training to practice or considering practice ownership. The platform allows physicians to view loans, income, and savings in one place, […]

Coral AI is a healthcare artificial intelligence company that aims to streamline administrative workflows for healthcare providers, ultimately accelerating patient access to care. The company’s AI-driven platform integrates with existing healthcare systems, including EHRs, fax lines, and payer portals, to automate complex administrative tasks. This includes patient intake, prior authorizations, billing, compliance, and patient outreach. […]

SamaCare is a healthcare AI company that provides a cloud-based workflow intelligence platform designed to streamline the prior authorization process for specialty medications. The company’s platform aims to reduce the administrative burden on medical practices, improve approval rates, and add predictability to patient care. By digitizing the often manual and paper-heavy prior authorization process, SamaCare […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.